化物B4是一种新的pyruvate carboxylase抑制剂,通过重编程巨细胞功能来缓解大肠炎
Qing-Hua Liang1, Qiu-Rong Li1, Zhong Chen1
1College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, Jiangsu, China.
概括
化物B4 (AB4) 通过准pyruvate carboxylase (PC) 来治疗结肠炎. 这种天然化合物抑制炎症和氧化应激,为结肠炎治疗提供了新的治疗途径.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 大肠炎涉及肠道炎症和上皮损伤,天然产品显示治疗潜力.
- 化物B4 (AB4),是一种来自Pulsatilla chinensis的素,表现出抗炎性质,但其在结肠炎中的确切机制尚不清楚.
研究的目的:
- 阐明在治疗大肠炎时,B4 (AB4) 氨基酸的分子标和机制.
- 为了研究酸盐碳酸酶 (PC) 在AB4的抗炎作用中的作用.
主要方法:
- 在大肠炎的细胞和动物模型中验证了AB4的抗炎作用.
- 通过亲和染色学识别了AB4的分子标,并通过蛋白质组学,分子对接,SPR和CETSA确认了结合.
- 研究了pyruvate carboxylase (PC) 在AB4的机制中的作用,使用过度表达和激动剂.
主要成果:
- 在体外,AB4抑制了NF-κB的激活,减少了氧化应激,并在体内抑制了结肠炎.
- 酸盐碳化酶 (PC) 被确定为AB4的直接分子标,与His879结合并改变其酶活性.
- AB4通过抑制PC活性来逆转LPS诱导的代谢重编程;PC激动剂在体内减少了AB4的治疗作用.
结论:
- 酸盐炭酸酶 (PC) 是AB4在调节性大肠炎中的直接细胞点.
- 在脂聚糖 (LPS) 驱动的炎症和氧化应激中,PC/酸盐代谢/NF-κB途径至关重要.
- PC 呈现出一种潜在的新型治疗肠炎治疗点.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
144
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
144
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
01:29Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128